Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botox to prevent radiation-induced salivary gland damage in head and neck cancer
2025-524720-22-00Phase 2Authorised
- Sponsor
- Faculty Hospital Kralovske Vinohrady
- Start
- Jun 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of botulinum toxin type A in head and neck squamous cell carcinoma (HNSCC), salivary gland damage and radiation-induced hyposalivation (RIX), sponsored by Faculty Hospital Kralovske Vinohrady. Primary endpoint: Change in salivary gland function by Tc99m scintigraphy. Planned start Jun 2026; status: authorised.
02
Drugs
botulinum toxin type A
03
Conditions
head and neck squamous cell carcinoma (HNSCC)salivary gland damageradiation-induced hyposalivation (RIX)
Beyond the preview
Go deeper on 2025-524720-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524720-22-00.